Virtus ETF Advisers’s Rigel Pharmaceuticals RIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $41.5K | Hold |
2,215
| – | – | 0.05% | 252 |
|
|
2025
Q1 | $39.8K | Buy |
+2,215
| New | +$39.8K | 0.05% | 228 |
|
|
2021
Q4 | – | Sell |
-10,466
| Closed | -$380K | – | 394 |
|
|
2021
Q3 | $380K | Sell |
10,466
-960
| -8% | -$34.9K | 0.17% | 182 |
|
|
2021
Q2 | $496K | Buy |
11,426
+2,229
| +24% | +$96.8K | 0.2% | 154 |
|
|
2021
Q1 | $315K | Buy |
9,197
+161
| +2% | +$5.51K | 0.13% | 233 |
|
|
2020
Q4 | $316K | Sell |
9,036
-8,088
| -47% | -$283K | 0.13% | 197 |
|
|
2020
Q3 | $411K | Sell |
17,124
-2,334
| -12% | -$56K | 0.22% | 164 |
|
|
2020
Q2 | $356K | Buy |
19,458
+3,334
| +21% | +$61K | 0.17% | 260 |
|
|
2020
Q1 | $252K | Sell |
16,124
-2,350
| -13% | -$36.7K | 0.1% | 248 |
|
|
2019
Q4 | $395K | Buy |
+18,474
| New | +$395K | 0.06% | 261 |
|
|
2018
Q4 | – | Sell |
-23,402
| Closed | -$751K | – | 364 |
|
|
2018
Q3 | $751K | Buy |
23,402
+1,603
| +7% | +$51.4K | 0.08% | 67 |
|
|
2018
Q2 | $617K | Buy |
21,799
+511
| +2% | +$14.5K | 0.55% | 129 |
|
|
2018
Q1 | $754K | Buy |
21,288
+11,415
| +116% | +$404K | 0.65% | 84 |
|
|
2017
Q4 | $383K | Sell |
9,873
-2,766
| -22% | -$107K | 0.48% | 62 |
|
|
2017
Q3 | $321K | Buy |
12,639
+1,156
| +10% | +$29.4K | 0.04% | 128 |
|
|
2017
Q2 | $313K | Buy |
11,483
+243
| +2% | +$6.62K | 0.05% | 115 |
|
|
2017
Q1 | $372K | Buy |
11,240
+1,077
| +11% | +$35.6K | 0.07% | 119 |
|
|
2016
Q4 | $242K | Buy |
+10,163
| New | +$242K | 0.07% | 150 |
|